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BACICGROUND: Late allograft loss remains a key area of concern. This study was 
aimed at determining the patient and renal allograft outcome and identifying the factors 
responsible for survival following transplantation with a living-related donor kidney at 
the Nairobi Hospital, Kenya. 
METHODS: Follow-up data for living-related donor graft recipients between 1988 and 
2001 was collected. Outcome measures studied were patient and graft survival. Graft 
loss was defined by the need for permanent renal dialysis, repeat transplantation or 
death with a functioning graft. The Kaplan-Meier method was used to estimate survival. 
Crude mortality rates per 100 person-years of follow-up were also calculated. Outcome 
status was correlated with age, sex, readmission, creatinine level, duration of follow-up 
and financial sustainability. The Fischer's exact test, X2 analysis and t-test were employed 
where appropriate. Logistic regression was used to detect independent risk factors for 
outcome. P C 0.05 was considered significant. 
RESULTS: Follow-up data were available for 45 of 53 patients. Six were subsequently 
lost to follow-up. The 1-year and 5-year patient survival was 77.8 and 63.1 O h  respectively. 
The overall mortality was 10.7 per 100 person-years of follow-up. Risk of mortality was 
higher in the first year after transplantation (approximately double). Female gender, 
elevated serum creatinine levels, readmission and non-sustainable finances adversely 
affected patient outcome on univariate analysis. Overall graft survival was 77.8 % at 1 
year and 52.7 O/O at 5 years. Most Deaths resulted from chronic allograft rejection and 
sepsis. 
CONCLUSION: Pharmacological manipulations with newer immunosuppressive agents 
could reduce allograft loss and impact positively on patient survival. 
Introduction 
The Important outcome measures to consider in 
renal transplantation analyses are patient and graft 
survival. There has been considerable improvement 
in patient survival over the last three decades with 
current global estimates of 95 percent and 90 percent 
survival at 1 and 5 years respectively'. The main 
determinants of this survival are however still not 
completely understood. Some results suggest older 
age of recipients, the male gender, the presence of 
diabetes and hypertension and cigarette smoking as 
the negative determinants of patient surviva112. With 
regard to graft outcome, both the short and long- 
term allograft survival has improved. This outcome 
has depended mainly o n  the quality of  
immunosuppression. The short-term outcome has 
been more substantial and attributable to the 
introduction of cyclosporin and OKT3 monoclonal 
antibody in the 1 9 8 0 ~ ) , ~  and more recently, 
mycophenolate mofetil and t ac ro l im~s~~ .  The relative 
risk of mortality for living donor transplant recipients 
is much less compared to cadaver transplant 
recipients2. The one- year survival rates now range 
between 80 and 90 percent4*'. 
Late allograft loss continues to be of concern. 
Chronic allograft nephropathy and death with a 
functioning graft are key underlying factors in this 
late loss. Our study sought to determine the long- 
term patient and renal-allograft survival and to 
identify factors that may affect survival at the Nairobi 
hospital. 
Patients and methods 
We studied all adults who underwent live donor renal 
transplantation between 1988 and 2001 at the Nairobi 
hospital. Details o n  donor  and recipient 
characteristics as well as the transplant protocol at 
the hospital were brought out in earlier publications8s9. 
A hospital transplant database does not exist. The 
authors therefore obtained follow-up data from 
indvidual physicians looking after the recipients post- 
operatively. Graft loss was defined by need for 
permanent dialysis, repeated transplantation or death 
with functioning graft. The I<aplan-Meier Method 
was used to estimate the survival of the patients and 
their grafts during follow-up. Short-term survival for 
both graft and patient was defined as survival for a 
period less or equal to one year. Long-term survival 
was that for longer than one year. 
Variables in the analysis included socio-demographic, 
clinical and transplant-related data. The  crude 
mortality rates per 100 person years of follow-up 
were calculated. Outcome status was correlated with 
age, sex, readmission, co-morbidity, and serum level 
of  creatinine, rejection episodes, financial 
sustainability, and compliance with medication, 
follow-up duration and the cause of end-stage renal 
failure. The Fischer's exact test and X2 analysis were 
used to determine statistical significance. Calculation 
of differences in lengths of follow-up, and average 
creatinine levels and age was determined by the t- 
test. Stepwise binary logistic regression was used to 
detect independent risk factors for poor outcome. 
Statistical significance of differences in survival 
distribution was determined by log-rank analysis. The 
data was presented in the form of frequency tables, 
charts and survival plots. 
Results 
Follow-up data were available for 45 (44 first time 
and one re-transplantations) out  of  53 eligible 
allograft recipients. The  recipients (average age 
42.0+11.81 years) were followed up for a total of 
1900 months (mean follow-up duration 42.22 
months; range 1-158 months). Six patients (13%) did 
not complete the follow-up. The 1-year and 5-year 
patient survival for this cohort was 77.8 and 63.1 
percent respectively. The calculated overall mortality 
rate was 10.7 per 100 person years of follow-up. 
There were more deaths in the first year after 
transplantation than during follow-up beyond one 
year. The mortality rate was 22.2/ 100 person-years 
of follow-up within the first post-transplantation year 
and 5.79/100 person-years thereafter. This difference 
in survival between the first and subsequent years 
of follow-up was statistically significant @ = 0.003, 
odds ratio 3.16, C/I 1.52-6.57) on univariate analysis. 
Fig.1 Patient Survival Plots After Renal 
Transplantation At Nairobi Hospital. 
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There were significantly fewer deaths among male 
recipients (8 out of 32). Conversely, the overall 
mortality was higher for female graft recipients (9 
out of 13, p = 0.008). Figure 1 depicts the overall 
Icaplan-Meier plot of survival and the effect of 
different genders on the survival curve. 
The other factors that adversely affected patient 
survival following transplantation included elevated 
serum creatinine levels (indicating sub-optimal graft 
function), readmissions (with various ailments or 
rejection), and lack of sustainable finances hence 
poor compliance with therapy (Table 1). There were 
no significant differences between survivors and non- 
survivors with respect to age of recipient at the time 
of transplantation and the presence of co-morbid 
disease (Table 1). 
In roughly half of the kidney transplant recipients 
the cause of  renal failure was chronic 
glomerulonephritis o r  diabetic kidney disease 
(chronic glomerulonephritis 26.7%, diabetes 22.2%, 
hypertension 15.6%, nephro/glomerulosclerosis 
15.6O/0, miscellaneous 19.9O0). The age and gender 
differences between the different diagnostic 
categories were not statistically significant. 
The proportion of non-survivors appeared higher 
in those recipients with primary glomerulonephritis 
(58.3%) than the other indications for transplantation 
(Hypertension 28.6%, Diabetes 28.6%, nephro/ 
glomerulosclerosis SO%, others 18.2%)(Fig.2). These 
observations were however not  significant in 
statistical terms (Table 1). The overall graft survival 
was 77.8 % at lyear and 52.7 % at 5 years. The female 
recipients had significantly worse graft outcome than 
males @=0.002). Graft outcome was also adversely 
affected by occurrence of at least an episode of acute 
rejection, readmission and duration of follow-up less 
than one year (P< 0.05). O n  logistic regression, 
rejection episodes had the most influence on graft 
survival. 
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We found that there were no statistically significant 
differences in graft survival with respect to recipient 
age and presence of co-morbid disease (Table 2). 
Six recipients died of chronic allograft rejection 
while another six succumbed due to sepsis. There 
were two operative deaths, two cardiovascular and 
one death due to malignancy 
Discussion 
This study provides results of long-term follow-up 
of patients undergoing renal transplantation in a 
single center in Africa. The follow-up rate of 74 %, 
although less than would be expected in a similar 
study in developed countries, is a high figure for 
Africa. The rate is expected to be much lower in 
public programs where financial and other social 
impediments are greater. Transplantation programs 
are available in only a few countries in Africa (10). 
To the best of our knowledge, our results represent 
the first long-term outcome results following kidney 
transplantation in Kenya and the East and Central 
Africa region. 
Our results indicate that the overall mortality for 
living donor transplant recipients was 10.7 per 100 
person years. The one and five year survival figures 
were 77.8 and 63.1 percent respectively. These figures 
depict higher mortality figures in comparison with 
those from the industrialized countries. The survival 
of patients undergoing renal transplantation has 
improved considerably in the latter countries over 
the past three decades with expected survival rates 
of 95 percent at 1 year and around 90 percent at 3-5 
years'. Although our figures appear to approach the 
results of the industrial World in the 1970s when 1- 
year survival figures were 85 percent for the young 
and 60% for older transplant recipients1, recent 
results from some large-volume centers convinces 
us that good outcome is possible in African hospitals. 
Analyzing over 4,000 kidney allograft recipients from 
the Brazilian renal Transplant registry, Sesso and his 
colleagues found patient 5-year survival rates of 69 
percent for living unrelated donors and 73.2 percent 
for cadaveric donors1'. 
We found that the risk of mortality was higher in 
the first year after transplantation (22.21100 patient 
years of follow-up) as compared to the later years 
(5.791100 person years of follow-up). This finding 
conforms to the results of studies done elsewhere2. 
In a Netherlands study of 1002 renal transplantations 
performed between 1966-1994, the crude mortality 
rate for living donor kidney transplant recipients was 
3.7 per 100 person years of follow-up in the first 
year and 0.9/100 person years of  follow-up 
thereafter. 
The higher mortality in the first year is thought to 
be due to transplant procedures, intensity of  
immunosuppression and related complications2. In 
our earlier analysis of the first 50 kidney recipients, 
twenty-eight patients (56.0%) had at least one 
complication, 28.0% had at least a rejection episode 
and seven died during the first 30 days after 
transplantation. They died of  sepsis, surgical 
complications, and immunosuppression-related 
complications9. 
Our results showed that male recipients and patients 
with sustainable finances had better survival than 
female recipients and those without sustainable 
income. The finding on  financial sustainability is not 
surprising as the immunosuppressive regimens to 
prevent and control rejection nephropathy are 
expensive. The implication of this finding to the 
development of national transplant programs in the 
African continent is that the programs will fail if 
allocation of funds by governments will not be 
sufficient. The  majority of those on  transplant 
waiting lists are poor and hence lacking in both 
employer support and health insurance to afford 
immune therapy. 
Although conflicting results have been 
p~b l i shed '~ - " J~J~  with regards to long-term survival, 
better 5-year patient survival with the use of  
cyclosporin continues to be reported14 The finding 
that male recipients have higher survival is in contrast 
with other studies. Females have higher patient and 
graft survivals in Netherlands as compared to 
males2~"j. We could find no obvious explanation for 
the superior survival in males. The smaller proportion 
of co-morbidity and rejection nephropathy in males 
as compared to female recipients may be part of the 
explanation. There was an instance where a female 
patient discontinued her immunosuppressive regime 
because the financier husband had lost his job. 
The other factors that were related to adverse patient 
outcome were elevated serum creatinine levels and 
being readmitted. Elevated creatinine levels denote 
diminishing kidney function (rejection). These factors 
are related and would have confounding effects on 
each other. It  was not surprising then that with 
regression analysis, only readmission remained as the 
independent predictor of mortality. 
The age of the patients and the presence of co- 
morbid disease as well as the underlying cause of 
end-stage renal failure did not have any statistical 
effect on overall survival- a finding that contrasts 
other results. Higher mortality rates have been 
reported for patients aged 40 years and above, both 
within and after the first year of tran~p1antation'~-". 
Although small, Arend et al, found a higher risk of 
mortality in the presence o f  diabetes and 
hypertension2.The number of kidney recipients we 
have followed is small. A larger pool of patients may 
give a different picture. It is also possible that the 
results extend those of Meier-Kriesche et al.Is. The 
authors found recipient age was a risk factor for 
development o f  chronic allograft failure in 
Caucasians and not African-Americans. 
The one and five-year graft survival was 77.8 and 
52.7 percent respectively. These survival figures are 
lower than in the West. The 1-year graft survival rate 
is 90% for recipients of living donor kidneys and 
77% for cadaver donor kidneyst9. In USA, between 
1988-1996, survival rate at 1 year for transplants from 
living donors increased from 88.8% in 1988 to 93.9% 
in 1996 (increase of 5.1 percentage  point^)^. Graft 
loss after transplantation may be due to acute 
rejection, primary non-function, graft thrombosis, 
recurrent kidney disease or death of patient with 
functioning graft. 
Our results indicate that the factors that had 
significant detrimental effect on survival of renal 
allografi 
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ts were rejection episodes, readmission, 
ender, and patient survival of less than one 
.he USA study, clinical acute rejection within 
year after transplantation had a detrimental 
I long-term graft survival4. 
logenesis of chronic allograft nephropathy 
ntry point for strategies to prevent late 
Irr failure. Early allograft damage caused by 
peritransplantational injuries and episodes of 
.ejection result in loss of functional nephrons. 
c:er both immunologic and non-immunologic 
(poor HLA matching, sub-optimal 
s suppression, non-compliance of patient, 
older donor, hypertension, cyclosporin toxicity) 
contribute to the development of chronic allograft 
nephropathy7. 
The current strategies to prevent allograft rejection 
should then include peri-operative management, 
prevention of acute rejection, treatment of severe 
rejection, and optimization of drug dosages beyond 
the first year and the treatment of hypertension. 
Optimal donor selection, shortening of cold ischemia 
and preferential use of living donors are the current 
~ogue~ ' ' ~~ ' .  Newer immunosuppressive drugs 
(Tacrolimus, Mycophenolate Mofetil, Sirolimus, 
Monoclonal antibodies against interleukin-2 
receptor) have reduced the incidence of acute 
rejection among recipients of renal allografts to as 
low as 10-30O/0~~ and it is anticipated that this lowered 
frequency will translate into decreased incidence of 
allograft loss. It has been shown in other studies also 
that acute rejection is an important predictor of 
chronic allograft nephropathf3sZ4. 
This study has several limitations. Retrospective 
analyses suffer from inherent flaws of missing data 
and author biases. Our results are from a medium 
sized private hospital in Nairobi, where the usual 
problems of limited resources for patient care are 
minimal. Its external validity can be questioned. 
Results from the public sector are necessary to 
confirm possibility of good surgical outcome. We 
have not analyzed patients on dialysis treatment to 
demonstrate survival advantage of  renal 
transplantation in this setting. Additionally other 
factors known to influence both patient and graft 
survival including surgical procedures, duration of 
cold ischaemia and dialysis treatment have not been 
considered in the analysis. Future prospective studies 
to validate the results presented are necessary. 
Conclusion 
Patient survival following renal transplantation was 
77.8 percent and 63.1 percent at one and five years 
after transplantation respectively, with overall 
mortality rate of 37.8 percent (10.7 per 100 person- 
years). Survival was a function of recipient gender, 
post-operative kidney function and sustainable 
finances. Graft survival was 77.8 percent at one year 
and 52.7 percent at five years. Rejection episodes were 
the major risk factor for poor graft outcome. 
It  would seem that our ideal patient for kidney 
transplantation was a male with adequate financial 
resources to keep the kidneys in optimal function 
after transplantation. Pharmacologic manipulations 
including the use of newer immunosuppressive 
regimens may reduce allograft loss and should impact 
positively on patient survival. 
T h e  outcome results appear inferior to  figures 
from the developed economies. Higher mortality 
during the early months after transplantation 
corroborates other studies. Other results indicate 
a protective effect of the female gender. Our  
smal l  s ample  s ize could  part ly explain the  
minimal effect of gender and co-morbidity o n  
outcome. T h e  effect of sustainable finances has 
implications o n  the development of transplant 
programs i n  the  continent. 
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